Christie Edward M III

SEC source: 0000785161-26-000178 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,345

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on July 15, 2026.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $112.40 to $112.43, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-26-000178 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,097

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.

SEC source: 0000785161-26-000146 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,086

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

SEC source: 0000785161-26-000123 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,452

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on April 15, 2026.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.11 to $106.17, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-26-000123 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,191

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-26-000004 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,182

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on January 15, 2026.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.82 to $102.90, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-26-000004 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,913

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0000785161-25-000108 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,904

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on October 15, 2025.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.20 to $123.21, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0000785161-25-000108 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,681

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-019245 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,674

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on July 15, 2025

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.48 to $106.68, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-019245 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,414

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-013139 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,406

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-25-012566 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,982

F1 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on April 15, 2025.

F2 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.48 to $102.56, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-012152 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,714

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $102.30. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-25-001394 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,709

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on January 15, 2025.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $94.35 to $94.41, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-25-001394 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,417

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001498710-24-000243 · wk-form4_1733433149.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 287,143

F1 · date: This Form 4 is being filed late due to inadvertent administrative error.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001127602-24-025655 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,411

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.17 per share paid on October 15,2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $97.62 to $97.63, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-025655 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,128

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-020550 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,122

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on July 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $86.61 to $86.80, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-020550 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,788

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-014068 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,782

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-013024 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,804

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on April 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.65 to $79.67, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-013024 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,490

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001498710-24-000145 · wk-form4_1712347691.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,343

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-24-000134 · wk-form4_1709760031.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 289,472

F1 · kind: The transaction reported represents the acquisition of shares by the issuer following settlement of the 2021 grant of performance share units with a performance period from January 1, 2021 through December 31, 2023.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-24-000088 · wk-form4_1706824357.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 287,220

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001127602-24-001542 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,488

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their directors fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the dividend of $0.15 per share paid on January 16, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $70.49 to $70.52, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-001542 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 16, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $71.45. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001498710-24-000037 · wk-form4a_1705616140.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 295,903

F3 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-24-000009 · wk-form4_1704229238.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,890

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-24-000037 · wk-form4a_1705616140.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 299,907

F1 · kind: The original Form 4, filed on January 2, 2024, is being amended by this Form 4 amendment to correct administrative error by changing the code from F to A for a transaction that occurred on December 28, 2023. The transaction reported represents the acquisition of shares by the issuer following the settlement of the 2021 grant of market share units with a performance period from January 1, 2021 through December 28, 2023.

F1 · balance_after: The original Form 4, filed on January 2, 2024, is being amended by this Form 4 amendment to correct administrative error by changing the code from F to A for a transaction that occurred on December 28, 2023. The transaction reported represents the acquisition of shares by the issuer following the settlement of the 2021 grant of market share units with a performance period from January 1, 2021 through December 28, 2023.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-23-000228 · wk-form4_1703885619.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 289,587

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001127602-23-028334 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 997

F1 · shares: Award of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001498710-23-000119 · wf-form4_168072516845133.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 295,840

F1 · kind: Grant of restricted stock units, vesting in one-third increments on April 3rd over 3 years.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-23-000101 · wf-form4_167831049540571.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,237

F1 · kind: The transaction reported represents the acquisition of shares by the issuer following settlement of the 2020 grant of performance share units with a performance period from January 1, 2020 through December 31, 2022.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-23-000061 · wf-form4_167528927111456.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,889

F1 · kind: Grant of restricted stock units, vesting in one-third increments on January 30th over 3 years.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-23-000026 · wf-form4_167407661444762.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 218,679

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-23-000013 · wf-form4_167278083379728.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,784

F1 · kind: The transaction reported represents the acquisition of shares by the issuer following settlement of a 2020 grant of performance share units with a performance period from January 1, 2020 through December 29, 2022.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-22-000386 · wf-form4_167232611376942.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,085

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-22-000111 · wf-form4_164686344056538.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,317

F1 · kind: The transaction reported represents the acquisition of shares by the issuer following settlement of a 2019-2021 grant of performance share units with a performance period from January 1, 2019 through December 31, 2021.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-22-000074 · wf-form4_164271444279153.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,485

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-22-000057 · wf-form4_164262694451011.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,970

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-22-000033 · wf-form4_164254085016753.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,019

F3 · kind: Grant of restricted stock units, vesting in one-third increments on January 13th over 3 years.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-22-000033 · wf-form4_164254085016753.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,106

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-22-000011 · wf-form4_164210874591081.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,453

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001498710-21-000056 · wf-form4_161550055713183.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,796

F1 · kind: The transaction reported represents the acquisition of shares by the issuer following settlement of a 2018-2020 grant of performance share units with a performance period from January 1, 2018 through December 31, 2020.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001209191-21-004602 · doc4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,466

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001209191-21-004602 · doc4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,547

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.

SEC source: 0001209191-21-004009 · doc4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 218,951

F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the company's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units.

F2 · balance_after: Includes restricted stock units.